VIROLOGIC ( 936848 ) charttechnisch vor Ausbruch - 500 Beiträge pro Seite

[zockbock]

Gestern mit News

SOUTH SAN FRANCISCO, Calif., April 14 /PRNewswire-FirstCall/ -- ViroLogic, Inc. today announced that data from a study published in the current issue of the journal AIDS support the clinical utility of its patented PhenoSense(TM) HIV assay for phenotypic analysis of anti-retroviral drug susceptibility information to guide therapeutic decisions in the management of HIV/AIDS patients.

This randomized clinical trial, conducted by researchers from the AIDS Clinical Trial Group (ACTG) 364, including researchers from Stanford University Medical Center, Harvard School of Public Health, Beth Israel Deaconess Medical Center, ViroLogic and Bristol-Myers Squibb, is the first published study to demonstrate that phenotypic drug susceptibility information is correlated with improved long-term virological outcomes.

"The data clearly showed that reduced susceptibility (i.e., resistance) in the PhenoSense HIV assay is an important independent risk factor for drug treatment failure, and provides clinicians with useful information to predict long-term treatment outcomes over almost 3 years," said Nick Hellmann, M.D., Vice President of Clinical Research at ViroLogic and one of the co-authors of the article. "This study reaffirms the predictive value of phenotypic tests and suggests that the use of the PhenoSense HIV assay in combination with other virus and patient parameters can help physicians select durable therapeutic regimens for HIV/AIDS patients."

In this study, a strong correlation between susceptibility in the PhenoSense HIV assay and virological outcome of multi-drug therapy was observed over a period of almost 3 years. Patients whose HIV was sensitive in the PhenoSense assay to more drugs in the prescribed anti-retroviral treatment regimen exhibited significantly slower virological failure (i.e., the inability of therapy to reduce viral load and maintain it at a low level) than patients whose virus was sensitive to fewer drugs. Based on the study findings, the researchers concluded that the PhenoSense HIV assay is a significant, independent predictor of long-term response to marketed anti-retroviral drugs among treatment-experienced patients.

Study Details

The trial was performed in 131 nucleoside reverse transcriptase inhibitor (NRTI-) experienced patients who had viral load greater than 2,000 copies of HIV RNA/mL of plasma. Results of the PhenoSense HIV assay at baseline were compared to the change in HIV viral load from 16 to 144 weeks following initiation of treatment with a 3- to 4-drug regimen, consisting of two NRTIs; efavirenz, a non-nucleoside reverse transcriptase inhibitor (NNRTI); and/or nelfinavir, a protease inhibitor. Virological failure of the 3- to 4-drug regimen was defined as two serial measurements of HIV viral load greater than 2,000 copies/mL.

Because cross-resistance to NRTIs is recognized as a monitoring and therapeutic challenge, the ability to accurately measure NRTI drug resistance and to show that those resistance measures accurately predict virological outcome in NRTI-experienced patients had been difficult. However, the PhenoSense HIV assay, which provides a highly sensitive measure of susceptibility to 16 anti-retroviral agents, proved to be significantly correlated to treatment outcomes in this study.

The trial data showed that a higher baseline viral load and lower baseline phenotypic susceptibility to drugs in the treatment regimen, as measured by the PhenoSense assay, were independently associated with virological failure of antiretroviral drug therapy.

Also, the findings confirmed that enhanced susceptibility, (referred to as "hyper-susceptibility") to efavirenz, as measured by the PhenoSense HIV assay, correlated with phenotypic resistance to the NRTI, zidovudine. Furthermore, hyper-susceptibility to efavirenz in the PhenoSense HIV assay was independently associated with a lowered risk of virological failure of the multi-drug therapy. PhenoSense HIV is the only commercial assay that currently reports hyper-susceptibility information.

About ViroLogic

ViroLogic is a biotechnology company advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious viral diseases such as AIDS and hepatitis. The company``s products are designed to help doctors optimize treatment regimens that lead to better patient outcomes and reduced costs. ViroLogic``s technology is also being used by numerous biopharmaceutical companies to develop new and improved antiviral therapeutics and vaccines targeted at emerging drug-resistant viruses. More information about the Company and its technology can be found on its World-Wide Web Site at http://www.virologic.com/.

Certain statements in this press release are forward-looking, including statements relating to the study results published in AIDS supporting the use of ViroLogic``s PhenoSense(TM) HIV assay as a source of information for therapeutic decisions in the management of HIV/AIDS patients. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the Company``s products may not continue to perform in the same manner as indicated in the study discussed in the press release, the risk that preliminary investigations initiated by governmental agencies may continue for a prolonged period and may not be concluded in the manner expected by ViroLogic, whether ViroLogic``s products will achieve market acceptance, the timing of pharmaceutical company clinical trials, whether payors will authorize reimbursement for its products, whether the Company will be able to expand its sales and marketing capabilities, whether the FDA or any other agency will decide to regulate its products or services, whether the Company encounters problems or delays in automating its processes, whether it successfully introduces new products, whether others introduce competitive products, whether intellectual property underlying its PhenoSense technology is adequate, whether it is able to build brand loyalty and expand revenues, and whether ViroLogic will be able to raise sufficient capital. For a discussion of other factors that may cause ViroLogic``s actual events to differ from those projected, please refer to the Company``s most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission.

ViroLogic, Inc.

© PR Newswire

[jojobada]

richtig ein Gap bei 2,60 könnte in kürze genommen werden
viel glück noch an alle

mfg jojo

[js200]

Hmmmmmmmmmmmmmmmmmmmm

http://www.investtech.com/nasdaq/ana/vlgc.htm

JS200

[zockbock]

Der kurzfristige Abwärtstrend wurde gestern bereits überwunden. Der langfristige verläuft bei rund 1,25.
MACD kurz vor Kaufsignal. Bin gespannt, wie es weiter geht.